@article{1a02f7bcd75440d1abfa08ccc10b21e4,
title = "Subcutaneous Atezolizumab: A Jab Without a Benefit",
keywords = "Antibodies, Monoclonal, Humanized, Humans, Janus Kinase 2",
author = "Peer, \{Cody J.\} and Zimmerman, \{Sara M.\} and Figg, \{William D.\} and Goldstein, \{Daniel A.\} and Ratain, \{Mark J.\}",
note = "Funding Information: This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health Grant ZIC SC 006537, and from the National Institute of General Medical Sciences, Grant T32 GM007019. Funding Information: Daniel Goldstein has institutional research funding from Merck, BMS, and Janssen and has received consulting fees from Vivio Health and owns stock in Vivio Health and TailorMed. Mark Ratain has served as a patent litigation consultant and expert witness on behalf of multiple generic pharmaceutical companies; has received consulting fees from Ascentage, Aptevo, Genentech, Pneuma Respiratory, and Shionogi; clinical trial funding from AbbVie, Dicerna, and Genentech; and other support from BeiGene. All other authors have declared no competing interests for this work. ",
year = "2022",
month = jan,
doi = "10.1002/cpdd.1061",
language = "English",
volume = "11",
pages = "134--135",
journal = "Clinical Pharmacology in Drug Development",
issn = "2160-763X",
publisher = "Wiley-Blackwell",
number = "1",
}